The state's inquiry is the latest hurdle for the direct-sales nutrition company.» Read More
CNBC's Andrew Ross Sorkin reports Third Point's Dan Loeb has bought more than a five percent stake in Herbalife.
This could be the most difficult earnings season in years, revealed "Mad Money" host Jim Cramer. Here’s what’s on his radar.
CNBC's Herb Greenberg's story on activist investor Robert Champan battling Bill Ackman on Herbalife boosted the stock more than 10 percent. John Hempton, Bronte Capital Management CIO and Greenberg, discuss.
Two widely followed hedge fund managers ended the year on divergent notes with Daniel Loeb handily beating the broader stock market with double-digit returns while David Einhorn posted only a modest single-digit annual gain after his flagship fund performed poorly at year end.
"We stand by everything we have said," activist investor Bill Ackman tells CNBC about his high-profile accusations against Herbalife.
Is Ackman sticking by his short position on HLF, and who else is getting into the stock? CNBC's Herb Greenberg reports the latest details.
There's nothing better than one activist taking on another, and that's just what Robert Chapman of Chapman Capital is doing to Pershing Square's Bill Ackman over Herbalife.
CNBC's Brian Sullivan reports shares of Herbalife popped 6.8 percent, and the FMHR traders discuss how to trade the stock now; and Alec Young, S&P Capital IQ, explains where he is seeing buying opportunities in the market.
Stocks eased off their lows but still finished in the red Wednesday, as weakness in the retail sector and ongoing worries over the looming "fiscal cliff" kept a damper on gains.
Herbalife is following the adage that the best defense is a good offense. Steven Russolillo, Wall Street Journal, explains.
Some of the names on the move ahead of the open.
Stocks ended in negative territory in a quiet, shortened trading session Monday, extending declines from the previous session, amid ongoing worries over the looming "fiscal cliff."
He who knows to run away, lives to trade another day!
Nutrition company Herbalife plans to host an analyst day shortly after the New Year, in response to a battery of charges leveled at the company by hedge fund guru Bill Ackman.
I have got some bad news for Herbalife CEO Michael Johnson. But surely it was far worse for him to learn the plans of Pershing Square's Bill Ackman.
Stocks ended modestly higher across the board Thursday, lifted by financials, after House Speaker John Boehner said he would continue to work on a solution to the avert the "fiscal cliff."
Check out which companies are making headlines after the bell Thursday.
Tim Ramey, senior research analyst at D.A. Davidson, explains why he has a buy on Herbalife. CNBC's Herb Greenberg, weighs in.
Bill Ackman delivered a detailed presentation today on what he considers to be wrong with Herbalife, reports CNBC's Kate Kelly.
Take a look at some of Thursday's midday movers: